CTLA4 and neoplasm: The TIDE score has been identified as a potent biomarker to predict the tumor response to anti-PD1 or anti-CTLA4 (Jiang et al., 2018), while the TMB score has also been validated as an available tool to help oncologists select patients who may benefit from ICIs (Choucair et al., 2020).